DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z98v36/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia-Pipeline Insights" report to their offering.
Summary
Community-Acquired Bacterial Pneumonia- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Community-Acquired Bacterial Pneumonia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Community-Acquired Bacterial Pneumonia Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
Community-Acquired Bacterial Pneumonia- Pipeline Insights Report covers the Community-Acquired Bacterial Pneumonia pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Community-Acquired Bacterial Pneumonia related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.
Scope
- The report provides a Community-Acquired Bacterial Pneumonia Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the Community-Acquired Bacterial Pneumonia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
-
Provides pipeline assessment by monotherapy and combination therapy
products, stage of development and molecule type
Key Topics Covered:
- Community-Acquired Bacterial Pneumonia Overview
- Community-Acquired Bacterial Pneumonia Pipeline Therapeutics
- Community-Acquired Bacterial Pneumonia Therapeutics under Development by Companies
- Community-Acquired Bacterial Pneumonia Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Community-Acquired Bacterial Pneumonia Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Community-Acquired Bacterial Pneumonia Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Community-Acquired Bacterial Pneumonia Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Community-Acquired Bacterial Pneumonia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Community-Acquired Bacterial Pneumonia - Discontinued Products
- Community-Acquired Bacterial Pneumonia - Dormant Products
-
Companies Involved in Therapeutics Development for Community-Acquired
Bacterial Pneumonia
For more information visit http://www.researchandmarkets.com/research/z98v36/communityacquired
